Bavarian Nordic injects debt for GSK vaccines
AniDimi/anidimi - stock.adobe.com
Denmark’s Bavarian Nordic will buy two commercial vaccines from GlaxoSmithKline for €796m, in a debt funded acquisition that will be refinanced next year in the equity market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts